Phosphodiesterase 5 inhibitor protects kidney against ischemia-reperfusion induced injury in rats

Nam, Jong Kil; Park, S.W.; Choi, Young-Kyu; Kim, T.N.

doi:10.1016/s1569-9056(16)30495-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, microcirculation disorders and endothelial dysfunction play an important role in the development of ischemic and reperfusion injuries (Bonventre and Yang 2011, Basile et al 2012, Sedaghat et al 2019. Previously, it was demonstrated that phosphodiesterase inhibitors have preconditioning properties in simulating ischemia-reperfusion in various organs and tissues, including kidney ischemia-reperfusion (Erol et al 2015, Zahran et al 2019, Nam et al 2020. Udenafil is also a type 5 phosphodiesterase inhibitor used in the treatment of erectile dysfunction, but the distinctive feature of udenafil is its selectivity.…”

Section: Introductionmentioning

confidence: 99%

Renoprotective effect of carbamylated darbepoetin and udenafil in ischemia-reperfusion of rat kidney due to the effect of preconditioning and inhibition of nuclear factor kappa B

Kostina¹,

Pokrovskaya²,

Poltev³

2021

RRP

View full text Add to dashboard Cite

Introduction: Acute kidney injury is a widespread complication in hospitalized patients, with a high mortality rate and long-term complications affecting prognosis and quality of life and with high human and financial costs. In addition, to date, no clear algorithm for the prevention of this type of damage has been developed. Materials and methods: The research was carried out on male Wistar rats. A 40-minute renal ischemia-reperfusion model was used to model acute kidney injury. Further, the renoprotective properties of carbamylated darbepoetin, udenafil and their combination were assessed based on the analysis of the biochemical studies’ results, dynamics of the renal status and the renal microvasculature, and the pathomorphological picture. A series of experiments was also carried out to assess the contribution of adenosine triphosphate-dependent potassium channels and nuclear factor kappa B to the renoprotective properties of the said agents. Results and discussion: Prophylactic administration of carbamylated darbepoetin at a dose of 50 µg/kg and udenafil at a dose of 8.7 mg/kg led to a statistically significant decrease in creatinine and blood urea nitrogen, an increase in glomerular filtration rate with a simultaneous decrease in fractional excretion of sodium, as well as an increase in the level of microcirculation in the kidneys and a decrease in the severity of damage according to the data of a pathomorphological examination at all time points of the experiment. A higher efficiency of correcting ischemic and reperfusion renal injuries was observed when using a combination of the said pharmacological agents. A series of experiments with glibenclamide demonstrated that its preliminary administration levels the renoprotective properties of carbamylated darbepoetin and udenafil. The ability of the studied pharmacological agents to reduce lipopolysaccharide-induced expression of nuclear factor kappa B in mononuclear cells was also demonstrated. The results of the research suggest that the renoprotective effects of carbamylated darbepoetin, udenafil, and their combination are realized through ATP-dependent potassium channels and nuclear factor kappa B. Conclusion: Pharmacological preconditioning with carbamylated darbepoetin and udenafil reduces the severity of acute kidney injury induced by ischemia-reperfusion. Graphical abstract:

show abstract